Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

ELOC (Q15369) - Overview - Molecular Target Synopsis

Protein


ELOC, Elongin-C
UniProt Q15369

Also Known as ELOC_HUMAN, ELOC, TCEB1

SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex) (PubMed:7821821). In embryonic stem cells, the elongin BC complex is recruited by EPOP to Polycomb group (PcG) target genes in order generate genomic region that display both active and repressive chromatin properties, an important feature of pluripotent stem cells., The elongin BC complex seems to be involved as an adapter protein in the proteasomal degradation of target proteins via different E3 ubiquitin ligase complexes, including the von Hippel-Lindau ubiquitination complex CBC(VHL). By binding to BC-box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes. Heterotrimer of an A (ELOA, ELOA2 or ELOA3), ELOB and ELOC subunit (PubMed:17997974). The elongin BC complex interacts with EPOP; leading to recruit the elongin BC complex to Polycomb group (PcG) target genes, thereby restricting excessive activity of the PRC2/EED-EZH2 complex (By similarity). Part of E3 ubiquitin ligase complexes with CUL5 or CUL2, RBX1 and a substrate adapter protein that can be either SOCS1, SOCS5, ELOA, VHL or WSB1 (PubMed:15590694). The elongin BC complex is part of a complex with hydroxylated HIF1A (PubMed:12050673, PubMed:12004076). Interacts with VHL (PubMed:10205047, PubMed:12050673). Interacts with TMF1 (PubMed:15467733). Interacts with SPSB1 (PubMed:17189197). posed of LIMD1, VHL, EGLN1/PHD2, ELOB and CUL2 (PubMed:11006129, PubMed:10205047, PubMed:12050673). Interacts with SPSB1. Interacts with KLHDC10; which may be an E3 ubiquitin ligase complex substrate recognition component (PubMed:23102700). Interacts with NOS2 in the presence of SPSB1 or SPSB2 or SPSB4 (PubMed:21199876).

6GMQ
PVHL:ELOB:ELOC IN COMPLEX WITH (4-(1H-PYRROL-1-YL)PHENYL)METHANOL
RCSB/PDB
Inspect Structure
See all 3D Structures for ELOC

Isoforms / Transcripts (Protein Coding)


Sub-cellular localization


UniProt: ELOC is active in the following subcellular-locations: nucleus.
GO terms: ELOC is active in the following subcellular-locations: cytosol, elongin complex, nucleoplasm.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project ELOC has gain in 12 cell-lines, loss in 2 cell-lines and no signal in 991 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are:

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are:

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are:

(see details)

3D Structures


For ELOC there are:
58 structures (191 chains) solved
2 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


ELOC has been screened with 4 compounds (4 bioactivities). (see details)